Merit Medical withdraws reimbursement application, pivots strategy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis
November 13, 2025 4:05 PM ESTSOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (CMS) has notified Merit that its application for Transitional Pass-Through (TPT) incremental payment for WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) procedures in the outpatient and ambulatory surgery center (ASC) settings requires further consideration prior to CMS making a final decision. CMS notified Merit that it has deferred Merits application for the WRAPSODY® CIE to the Calendar Year 2027 Outpatient Prospective Payment System rule, making January 1, 2027, the earliest possible effective... More
